Ozempic vs Wegovy vs Mounjaro: What Is the Difference and Which Fits Which Goal? (2026)
By Dr. Frank Yap, MD · Published 2026-10-05 · Last updated 2026-10-05 · Reading time about 10 minutes
Quick Answer
Ozempic and Wegovy are both semaglutide; Mounjaro is tirzepatide. Ozempic and Mounjaro are labeled for type 2 diabetes, while Wegovy is labeled for weight management (Mounjaro's weight-management sibling is Zepbound). In the SURPASS-2 diabetes trial, tirzepatide lowered A1C and body weight more than semaglutide 1 mg over 40 weeks. The best fit depends on diagnosis, heart and kidney history, tolerability and cost.
In this article
- What is each medicine and what is it approved for?
- Ozempic vs Wegovy: same molecule, what changes?
- Ozempic vs Mounjaro: what does the head-to-head trial show?
- Wegovy vs Mounjaro: which is better for weight loss?
- Three-way comparison table
- Which fits which goal?
- Side effects and who should avoid them
- What happens if you stop?
- Cost and access?
- AI personalization guide
- Frequently asked questions
- References
What is each medicine, and what is it approved for?
Ozempic and Wegovy contain semaglutide, and Mounjaro contains tirzepatide. All three are once-weekly injections. Semaglutide activates the GLP-1 receptor. Tirzepatide activates both the GIP and GLP-1 receptors.
.png "Best Weight Loss Peptides")
Zepbound, a fourth brand, is tirzepatide labeled for weight management and is covered in our four-way comparison with Zepbound.
Evidence tier: regulatory facts from FDA labeling; indications can change, so confirm in the current prescribing information.
Ozempic vs Wegovy: same molecule, so what changes?
The molecule is identical; the labeled purpose, dose ceiling and pens differ. Ozempic comes in doses up to 2 mg weekly and is labeled for type 2 diabetes. Wegovy goes up to 2.4 mg weekly and is the version studied and labeled for weight management.
- Weight effect: In STEP 1 (adults with obesity, no diabetes), semaglutide 2.4 mg produced about 14.9% average weight loss at 68 weeks versus 2.4% with placebo. CEBM Level 2.
- Higher Ozempic dose: In SUSTAIN FORTE, semaglutide 2 mg lowered A1C and body weight more than 1 mg at 40 weeks in people with type 2 diabetes. CEBM Level 2.
- Outcomes: Wegovy's cardiovascular indication rests on the SELECT trial (17,604 adults with overweight or obesity and established cardiovascular disease, no diabetes), where semaglutide 2.4 mg lowered major cardiovascular events by about 20% (hazard ratio 0.80). CEBM Level 2.
- Prescribing: Using Ozempic for weight loss is off-label. Doses are not interchangeable between the two products, so a switch is a prescriber decision.
Ozempic vs Mounjaro: what does the head-to-head trial show?
In people with type 2 diabetes, tirzepatide lowered A1C and weight more than semaglutide 1 mg. SURPASS-2 was a 40-week randomized, open-label trial of about 1,880 adults with type 2 diabetes inadequately controlled on metformin. All three tirzepatide doses were superior to semaglutide 1 mg for both outcomes.
SURPASS-2 (Frias 2021). Evidence tier: CEBM Level 2 (open-label RCT).
Caveats that matter when reading this result
- The comparator was semaglutide 1 mg, not the 2 mg maximum Ozempic dose. An indirect comparison of tirzepatide with semaglutide 2 mg found similar results for tirzepatide 5 mg and larger reductions with 10 and 15 mg, but indirect comparisons carry more uncertainty than a head-to-head trial.
- The trial measured glycemic and weight outcomes, not heart or kidney events. Ozempic holds labeled cardiovascular and kidney indications in type 2 diabetes. Tirzepatide's cardiovascular trial (SURPASS-CVOT) compared it with dulaglutide, not semaglutide, so check the current label for any cardiovascular indication.
- Average results hide individual variation. Some people respond better to one drug than the other.
Wegovy vs Mounjaro: which is better for weight loss?
Tirzepatide produces larger average weight loss than semaglutide, but Mounjaro is labeled for diabetes, so the like-for-like weight comparison is Wegovy vs Zepbound. Mounjaro and Zepbound are the same drug. The head-to-head weight trial, SURMOUNT-5, compared those two molecules at the maximum tolerated dose in 751 adults with obesity or overweight and no diabetes.
SURMOUNT-5 (Aronne 2025). Evidence tier: CEBM Level 2 (open-label RCT). The trial excluded type 2 diabetes, so results may differ in people with diabetes.
Weight-loss response also varies by sex and by dose reached. Women lost more than men in both arms, and the average is less informative for any single person than for a population.
How do Ozempic, Wegovy and Mounjaro compare side by side?
The cards below summarize US labeling and headline trial data as of October 2026. Cross-trial figures come from different populations, so use them as context, not as a ranking.
Which medicine fits which goal?
Goal, diagnosis and coexisting conditions drive the choice, not the brand name. The table is a discussion guide for a prescriber visit, not a recommendation.
| Situation | What tends to matter |
|---|---|
| Type 2 diabetes with heart disease or chronic kidney disease | Ozempic has labeled cardiovascular and kidney indications in this setting. |
| Type 2 diabetes where maximum A1C and weight reduction are priorities | Mounjaro produced larger average reductions than semaglutide 1 mg in SURPASS-2. |
| Obesity without diabetes | Wegovy is labeled for it; Zepbound (tirzepatide) produced larger average loss in head-to-head data. |
| Obesity with established heart disease | Wegovy has randomized cardiovascular outcome data (SELECT) and a labeled indication. |
| Prior pancreatitis, personal or family medullary thyroid carcinoma or MEN 2, pregnancy | Typically contraindicated or needing specialist judgment for the whole class. |
| Insurance or budget limits | Formulary status and manufacturer programs often decide what is practical. |
What are the side effects, and who should avoid these medicines?
The side-effect profile is similar across all three because they share a drug class. Nausea, vomiting, diarrhea, constipation and abdominal discomfort are the most common, usually peaking during dose escalation. Slow dose increases are the main way prescribers improve tolerability.
- Gallbladder disease, pancreatitis, and dehydration that can injure the kidneys.
- Delayed gastric emptying; tell anesthesia teams about use before procedures because of aspiration risk.
- Low blood sugar when combined with insulin or sulfonylureas.
- Worsening diabetic retinopathy in some people with existing retinopathy when glucose falls quickly.
- Tirzepatide can reduce the effectiveness of oral hormonal contraceptives; labeling advises a non-oral or added barrier method around starting and each dose increase.
Boxed warning (all three products)
Semaglutide and tirzepatide carry a boxed warning about thyroid C-cell tumors seen in rodents. They are contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and they are not used in pregnancy. Seek urgent care for a neck lump, trouble swallowing, persistent hoarseness or severe abdominal pain.
Evidence tier: CEBM Level 2 for pivotal-trial adverse events; labeling reflects regulatory review of the full evidence base.
What happens to weight and blood sugar if you stop?
Most people regain a substantial part of the weight after stopping, and blood sugar control can worsen in type 2 diabetes. In the STEP 1 extension, people who stopped semaglutide regained about two thirds of their prior loss within a year. In SURMOUNT-4, people switched from tirzepatide to placebo regained about 14% of body weight while those who continued lost a further 5.5%. CEBM Level 2. For this reason these are generally treated as long-term therapies, with any plan to stop made with a prescriber.
How much do they cost?
Prices vary widely by product, dose, insurer and pharmacy, and they change often. In the US, list prices run roughly US$1,000 to US$1,350 per month for these medicines. Manufacturer self-pay programs and savings cards can bring costs far lower for some products and coverage situations, and self-pay options are not the same for every brand. Treat any figure as a snapshot and confirm it on the manufacturer or pharmacy site.
How can you use this article with Claude, ChatGPT, Gemini and Perplexity?
AI assistants help you prepare questions and organize information; they do not choose a prescription. Avoid pasting identifying details, lab reports or records into a general-purpose assistant, and verify every drug fact against prescribing information.
Ask each assistant to name its sources and their dates, and treat unsourced numbers as unverified.
Frequently asked questions
Is Ozempic the same as Wegovy?
Both contain semaglutide from Novo Nordisk. Ozempic is labeled for type 2 diabetes and tops out at 2 mg weekly. Wegovy is labeled for chronic weight management and related indications and is dosed up to 2.4 mg weekly. They are separate prescriptions with different pens, so one is not simply swapped for the other.
Is Mounjaro better than Ozempic?
For type 2 diabetes, tirzepatide (Mounjaro) lowered A1C and weight more than semaglutide 1 mg in the 40-week SURPASS-2 trial. That does not make it better for every person. Ozempic has labeled cardiovascular and kidney indications in type 2 diabetes, and tolerability, cost and coverage also matter.
Is Wegovy stronger than Ozempic?
Wegovy's top dose (2.4 mg) is higher than Ozempic's (2 mg), and Wegovy is the version studied and labeled for weight management. In STEP 1, semaglutide 2.4 mg produced about 14.9% average weight loss at 68 weeks. Ozempic is labeled for diabetes, and its weight effect is usually smaller.
Is Mounjaro approved for weight loss?
In the US, Mounjaro is labeled for type 2 diabetes, not weight loss. Its sister brand Zepbound contains the same drug, tirzepatide, and is labeled for chronic weight management. Prescribing Mounjaro for weight loss is off-label, and coverage for off-label use is often limited.
Can I switch between Ozempic, Wegovy and Mounjaro?
Switching is a prescriber decision. Doses are not interchangeable across semaglutide and tirzepatide, and the right starting dose after a switch depends on your current dose, tolerance and goals. Do not convert doses on your own or combine two of these medicines.
Which has more side effects?
The profile is similar across the three: nausea, vomiting, diarrhea and constipation are most common, mainly during dose escalation. Higher doses tend to cause more gastrointestinal effects. All three carry a boxed warning about thyroid C-cell tumors in rodents and are contraindicated with a history of medullary thyroid carcinoma or MEN 2.
Do Ozempic, Wegovy and Mounjaro cost the same?
No. Prices vary by product, dose, insurance and pharmacy, and they change frequently. List prices in the US run roughly US$1,000 to US$1,350 per month, while manufacturer self-pay and savings programs can be far lower. Confirm current prices with the manufacturer or pharmacy before deciding.
References and sources
- Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021. doi:10.1056/NEJMoa2107519. Summary: Eli Lilly SURPASS-2 release
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021. doi:10.1056/NEJMoa2032183
- Aronne LJ et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025. doi:10.1056/NEJMoa2416394. Summary: American College of Cardiology journal scan
- Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023. doi:10.1056/NEJMoa2307563
- Indirect comparison of tirzepatide and semaglutide 2 mg (SURPASS-2 and SUSTAIN FORTE). Diabetes Obes Metab. 2022. PubMed Central
- Frias JP et al. Efficacy and safety of semaglutide 2.0 mg versus 1.0 mg once weekly (SUSTAIN FORTE). Lancet Diabetes Endocrinol. 2021.
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022.
- Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024.
- FDA prescribing information for Ozempic, Wegovy and Mounjaro via Drugs@FDA. Confirm current indications and doses here.
Evidence key (CEBM)
Level 1: systematic review of randomized trials. Level 2: individual randomized trial or strong observational study. Level 3: non-randomized cohort or case-control. Level 4: case series. Level 5: expert opinion or mechanism-based reasoning. Tiers follow the Oxford CEBM scheme and describe study design, not the size or relevance of an effect for any one person.
Pricing, approvals and regional availability change frequently. This article was last updated on 5 October 2026 and will be revised on this same URL as new data and labeling changes appear. Always confirm current details with an official source and a licensed prescriber.
.png)
.png)
.png)
.png)
Comments
Post a Comment